AM-2201 is a potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the CB1 and CB2 receptors, respectively. AM-2201 acts as a potent but nonselective full agonist for the cannabinoid receptor. The physiological actions and metabolism of AM2201 have not been characterized.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Source||Drug Alcohol Depend (2017). Figure 2. AM2201|
|Concentrations||0.1 – 0.3 mg/kg|
|Incubation Time||3 h|
|Results||THC and XLR-11 were the least potent of the cannabinoids, while CP55,940 was the most potent. JWH-018 and AM2201 had comparable potency at increasing BP and were intermediate between CP55,940 and THC.|
Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism.
Hutter M, et al. J Mass Spectrom. 2013 Jul;48(7):885-94. PMID: 23832945.
First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201.
McQuade D, et al. Eur J Clin Pharmacol. 2013 Mar;69(3):373-6. PMID: 22936123.
|Related Cannabinoid Products|
BAY-59-3074 is a novel cannabinoid CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors, respectively.
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor.
|WIN 55212-2 mesylate
WIN 55212-2 is a potent nanomolar affinity cannabinoid receptor agonist with Ki of 62.3 and 3.3 nM at the human cloned CB1 and CB2 receptors respectively.
CP 945598 (Otenabant) is a selective, high affinity, competitive CB1 receptor antagonist with Ki of 0.7 nM.
BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.